Key Takeaways Novo Nordisk won FDA approval for Awiqli, a once-weekly basal insulin for adults with type II diabetes.Awiqli showed strong HbA1c reduction in the phase IIIa ONWARDS studies vs. daily basal insulin.NVO plans a U.S. launch of the FlexTouch device in the second half of 2026 after global approvals.Novo Nordisk (NVO) announced that the FDA has approved Awiqli injection as the first and only once-weekly, long-acting basal insulin icodec for adults with type II diabetes (T2D). The therapy is indicat ...

Over the past year, the two leaders in the obesity drug market, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have lagged broader equities, though the latter has performed substantially worse than the former. Still, analysts predict that this therapeutic area will soar over the next decade, and there is a good chance these two will maintain their edge over their peers given their pipelines. But which one is a better buy? Comparing their weight loss portfolios Eli Lilly's weight loss medicine, Zepbou ...

Conventional wisdom increasingly frames Novo Nordisk A/S ( NVO ) as the loser in its battle with Eli Lilly and Company ( LLY ) for the obesity drug market. I think that’s wrong. The analogy here isn’t Netflix versus Blockbuster, where oneThe Edson Spencer Professor of Strategy and Technological Leadership at the University of Minnesota Carlson School of Management Alfred Marcus' most recent book, Comeback: Can Great Companies Rise Again is available on Amazon. He is host of the popular New Books Network Pod ...

Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026 ...

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve .. Read More ...

司美格鲁肽在中国的核心化合物专利到期，该药曾是诺和诺德业绩增长的核心引擎。 作者 | 小鑫 编辑 | 小白 制图:市值风云APP 3月27日消息 | 专利到期打破垄断 3月27日消息，诺和诺德司美格鲁肽在中国的核心化合物 专利到期。这意味着这款全球关注的GLP-1长效类似物, 因显著的减重降糖效果而长期垄断的格局被打破。 NHH 免责声明： 本报告（文章）是基于上市公司的公众公司属性、以上市公司根据其法定义务公开披露的信息（包括但 不限于临时公告、定期报告和官方互动平台等）为核心依据的独立第三方研究；市值风云力求报告（文章）所载内 容及观点客观公正，但不保证其准确性、完整性、及时性等；本报告（文章）中的信息或所表述的意见不构成任何 投资建议，市值风云不对因使用本报告所采取的任何行动承担任何责任。 以上内容为 市值风云APP 原创 未获授权 转载必究 1. 创新药/多靶点研发 众生药业 甘李药业 常山药业 信立泰 博瑞医药 2. 生物类似药/仿制药 o te 华东医药 通化东宝 翰宇药业 丽珠集团 双鹭药业 德展健康 3. 上游原料药/中间体 ST诺泰 奥锐特 圣诺生物 海翔药业 皓元医药 普洛药业 月68 4 ...

整理 | GLP1减重宝典内容团队 3月中国发展高层论坛期间，诺和诺德全球执行副总裁林意明 （Emil Kongshøj Larsen） 连续释放了几项更具体的在华计划。和此前 偏宏观的"看好中国市场"不同，这次公司给出的动作已经比较清晰，核心集中在三条线上：继续加大本地化研发和生产投入，进一步把 中国纳入全球同步创新体系，以及围绕肥胖症搭建更完整的诊疗和服务生态。商务部3月20日披露，林意明在北京与商务部副部长凌激 会面时明确表示，诺和诺德愿进一步加大对华投入，扩大本地化生产和研发。 第一项新计划，是继续把中国本地研发和生产能力往上提。公司公开材料显示，诺和诺德目前已经形成天津生产、北京研发、上海商业 运营与创新三大引擎的在华布局，累计在华投资超过170亿元人民币。更具体的新增动作是，2025年公司已在上海成立开放创新中心， 并与当地机构开展创新转化合作；天津生产基地的扩建项目预计在2026年底竣工，进一步提升本地生产保障能力。换句话说，诺和诺德 这次不是单纯强调"继续深耕中国"，而是在把新增投入直接落到研发和制造两端。 第五项新计划，是继续强化现有肥胖症产品在中国的落地。诺和诺德2024年已将诺和盈引入中 ...

当地时间3月26日，诺和诺德在年度股东大会上宣布任命美国糖果巨头玛氏（Mars）公司首席执行官 波尔·魏拉赫（Poul Weihrauch）为董事会观察员。诺和诺德表示，减重药市场正越来越受消费者驱 动，公司正在研究消费者行为。 编辑 ｜ 钉钉 记者｜钱童心 ...

Companies Novo Nordisk A/S Reporting by Carlos Méndez in Mexico City; Editing by Rashmi Aich Our Standards: The Thomson Reuters Trust Principles., opens new tab US FDA approves Novo's insulin injection for type 2 diabetes | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little REFILE - CORRECTING LOCATION Purchase Licensing Rights, opens new tab Follow March ...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per weekNovo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026. Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL ...